ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ONXX Onyx Pharmaceuticals, Inc. (MM)

124.70
0.00 (0.00%)
15 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Onyx Pharmaceuticals, Inc. (MM) NASDAQ:ONXX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 124.70 0 01:00:00

Rigrodsky & Long, P.A. Announces Investigation Of Onyx Pharmaceuticals, Inc. Buyout

26/08/2013 7:02pm

Business Wire


Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts.

Rigrodsky & Long, P.A.:

  • Do you own shares of Onyx Pharmaceuticals, Inc. (NASDAQ GS: ONXX)?
  • Did you purchase any of your shares prior to August 25, 2013?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Onyx Pharmaceuticals, Inc. (“Onyx” or the “Company”) (NASDAQ GS: ONXX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Amgen Inc. (“Amgen”) (NASDAQ GS: AMGN) in a transaction valued at approximately $10.4 billion.

Click here to learn more: http://www.rigrodskylong.com/investigations/onyx-pharmaceuticals-inc-onxx.

Under the terms of the agreement, public shareholders of Onyx will receive $125.00 per share in cash for each share of Onyx they own.

The investigation concerns whether Onyx’s board of directors failed to adequately shop the Company and obtain the best possible value for Onyx’s shareholders before entering into an agreement with Amgen. According to Yahoo! Finance, at least one analyst has set a price target for Onyx stock at $160.00 per share.

If you own the common stock of Onyx and purchased your shares before August 25, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth Rigrodsky or Shaye Fuchs at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/onyx-pharmaceuticals-inc-onxx.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.Seth RigrodskyShaye Fuchs888-969-4242516-683-3516Fax: 302-654-7530info@rl-legal.comhttp://www.rigrodskylong.com

1 Year Onyx Pharmaceuticals, Inc. (MM) Chart

1 Year Onyx Pharmaceuticals, Inc. (MM) Chart

1 Month Onyx Pharmaceuticals, Inc. (MM) Chart

1 Month Onyx Pharmaceuticals, Inc. (MM) Chart

Your Recent History

Delayed Upgrade Clock